NCT01035658 - Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

June 30, 2012

Study Completion Date

March 31, 2014

Conditions

Ovarian CancerFallopian Tube CancerPeritoneal Carcinoma

Interventions

DRUG

Pazopanib

All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.

DRUG

Doxil

Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle

Trial Locations (4)

32804

Florida Hospital Cancer Insitute, Orlando

33901

Florida Cancer Specialists, Fort Myers

37023

Tennessee Oncology, PLLC, Nashville

45242

Oncology Hematology Care, Cincinnati